Wells Fargo analyst Stephen Baxter raised the firm’s price target on McKesson (MCK) to $772 from $766 and keeps an Equal Weight rating on the shares. The firm is updating model following solid Q1 2026 earnings. Beyond the Norway divestiture accounting impact, Wells’ estimates for Medical and U.S. Pharma are modestly higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strong Long-Term Growth Potential Justifies Buy Rating Despite Limited Immediate Upside
- McKesson’s Earnings Call Highlights Strong Growth and Strategic Moves
- McKesson price target raised to $830 from $824 at TD Cowen
- McKesson Corporation Reports Strong Q1 2026 Results
- McKesson’s Strong Performance and Strategic Moves Earn a Buy Rating from Charles Rhyee